Skip to main content

Advertisement

SpringerLink
Log in

Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial–mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

To explore the mechanism of miR-202-5p targeting the expression of PIK3CA and mediating the activation of PI3K/Akt/mTOR signaling pathway on the proliferation, invasion, and epithelial–mesenchymal transition (EMT) of cervical cancer. The objects of study were 105 cases of cervical cancer and their corresponding normal tissues. qRT-PCR was used to detect the expression of miR-202-5p and PIK3CA in adjacent normal tissue and cervical cancer tissue. Dual luciferase reporter assay was used to verify the targeting relationship between miR-202-5p and PIK3CA gene. Human cervical cancer cell lines HPV-16E6, SiHa, HeLa, and CaSki were purchased for our cell experiments. The expression levels of PIK3CA in the cells were detected by qRT-PCR. The cell line with higher expression levels was selected to complete the follow-up experiment. The cultured cells were transfected and divided into the miR-202-5p mimic NC group, miR-202-5p mimic group, miR-202-5p inhibitor NC group, miR-202-5p inhibitor group, siRNA-PIK3CA NC group, siRNA-PIK3CA group, miR-202-5p inhibitor NC + siRNA-PIK3CA NC group, miR-202-5p inhibitor + siRNA-PIK3CA NC group, and miR-202-5p inhibitor + siRNA-PIK3CA group. QRT-PCR was used to detect the expression of miR-202-5p. Western blot and qRT-PCR were applied to detect the mRNA and protein expression levels of related pathway proteins (PIK3CA, PI3K, PTEN, p-Akt1, and p-mTOR) and epithelial–mesenchymal transition-related factors (N-cadherin, E-cadherin, and vimentin). Cell proliferation was detected by plate colony formation assay. Transwell assay was used to detect the invasion ability of each group. When compared with the adjacent tissues, PIK3CA mRNA expression level was significantly increased and miR-202-5p expression level was significantly decreased in cervical cancer tissues (all P < 0.05). PIK3CA was a target gene of miR-202-5p. The mRNA expression level of PIK3CA in SiHa cervical cancer cells was significantly higher than that in CaSki, HeLa, and HPV-16E6 cells (all P < 0.05), and SiHa cervical cancer cells were selected to complete the follow-up experiments. When compared with the corresponding NC group, the expression of miR-202-5p in miR-202-5p mimic group was increased. In addition, the mRNA and protein expression levels of E-cadherin and PTEN in miR-202-5p mimic and siRNA-PIK3CA groups were increased, and the protein expression of p-Akt1 and p-mTOR was decreased, and also, the mRNA and protein expression levels of PIK3CA, PI3K, N-cadherin, and vimentin were decreased (all P < 0.05); in miR-202-5p inhibitor group, the expression levels of miR-202-5p, E-cadherin, and PTEN decreased, the protein expression of p-Akt1 and p-mTOR increased, and the mRNA and protein expression of PIK3CA, PI3K, N-cadherin, and vimentin increased in miR-202-5p inhibitor group (all P < 0.05); in miR-202-5p inhibitor + siRNA-PIK3CA group, the expression of miR-202-5p decreased (P < 0.05), but the mRNA and protein expression of PIK3CA, PI3K, p-Akt1, p-mTOR, N-cadherin, E-cadherin, and vimentin had no significant changes (all P > 0.05). When compared with the corresponding NC group, the number of cell clones in miR-202-5p mimic group and siRNA-PIK3CA group was decreased, and the invasion ability of miR-202-5p inhibitor group was increased, and the invasion ability was enhanced (all P < 0.05); miR-202-5p inhibitor + siRNA-PIK3CA group showed no significant change in the number of cell clones and the rate of invasion (P > 0.05). In conclusion, the overexpression of miR-202-5p can suppress PIK3CA gene expression and the activation of PI3K/Akt/mTOR signaling pathway to suppress the proliferation, invasion, and EMT of cervical cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data availability

The datasets supporting the conclusions of this article are included within the article.

References

  1. Shrestha AD, Neupane D, Vedsted P, Kallestrup P (2018) Cervical cancer prevalence, incidence and mortality in low and middle income countries: a systematic review. Asian Pac J Cancer Prev 19(2):319–324

    PubMed  PubMed Central  Google Scholar 

  2. Clifford GM, Tully S, Franceschi S (2017) Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer. Clin Infect Dis 64(9):1228–1235

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tao X, Austin RM, Zhang H, Zhang L, Xiao J, Wang L, Zhou X, Zhao C (2015) Pap test reporting rates for conventional smear and liquid-based cervical cytology from the largest academic women’s hospital in china: analysis of 1,248,785 pap test reports. Acta Cytol 59(6):445–451

    Article  PubMed  Google Scholar 

  4. Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A, Galazios G (2016) Cervical cancer: screening, diagnosis and staging. J BUON 21(2):320–325

    PubMed  Google Scholar 

  5. Hu Z, Ma D (2018) The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med 7(10):5217–5236

    Article  PubMed  PubMed Central  Google Scholar 

  6. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW, Wong JB (2018) Screening for cervical cancer: US preventive services task force recommendation statement. JAMA 320(7):674–686

    Article  Google Scholar 

  7. Li H, Wu X, Cheng X (2016) Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27(4):e43

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Chopra S, Gupta M, Mathew A, Mahantshetty U, Engineer R, Lavanya G, Gupta S, Ghosh J, Thakur M, Deodhar K, Menon S, Rekhi B, Bajpai J, Gulia S, Maheshwari A, Kerkar R, Shylasree TS, Shrivastava SK (2018) Locally advanced cervical cancer: a study of 5-year outcomes. Indian J Cancer 55(1):45–49

    Article  PubMed  Google Scholar 

  9. Kokka F, Bryant A, Brockbank E, Powell M, Oram D (2015) Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database Syst Rev 4:CD010260

    Google Scholar 

  10. Sadri Nahand J, Moghoofei M, Salmaninejad A, Bahmanpour Z, Karimzadeh M, Nasiri M, Mirzaei HR, Pourhanifeh MH, Bokharaei-Salim F, Mirzaei H, Hamblin MR (2020) Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: a review. Int J Cancer 146(2):305–320

    Article  CAS  PubMed  Google Scholar 

  11. Pardini B, De Maria D, Francavilla A, Di Gaetano C, Ronco G, Naccarati A (2018) MicroRNAs as markers of progression in cervical cancer: a systematic review. BMC Cancer 18(1):696

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Gao L, Zhang LJ, Li SH, Wei LL, Luo B, He RQ, Xia S (2018) Role of miR-452-5p in the tumorigenesis of prostate cancer: a study based on the Cancer Genome Atl(TCGA), gene expression omnibus (GEO), and bioinformatics analysis. Pathol Res Pract 214(5):732–749

    Article  CAS  PubMed  Google Scholar 

  13. Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C, Foti M (2019) Deciphering miRNAs’ action through miRNA editing. Int J Mol Sci 20(24):6249

    Article  PubMed Central  CAS  Google Scholar 

  14. Huang Y (2018) The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med 22(12):5768–5775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Akhtar MM, Micolucci L, Islam MS, Olivieri F, Procopio AD (2019) A practical guide to miRNA target prediction. Methods Mol Biol 1970:1–13

    Article  CAS  PubMed  Google Scholar 

  16. Asiaf A, Ahmad ST, Arjumand W, Zargar MA (2018) MicroRNAs in breast cancer: diagnostic and therapeutic potential. Methods Mol Biol 1699:23–43

    Article  CAS  PubMed  Google Scholar 

  17. Bertoli G, Cava C, Castiglioni I (2015) MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 5(10):1122–1143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Svoronos AA, Engelman DM, Slack FJ (2016) OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 76(13):3666–3670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rupaimoole R, Slack FJ (2017) MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 16(3):203–222

    Article  CAS  PubMed  Google Scholar 

  20. Tutar Y (2014) miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol 15(5):429

    Article  CAS  PubMed  Google Scholar 

  21. Mishra S, Yadav T, Rani V (2016) Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol 98:12–23

    Article  PubMed  Google Scholar 

  22. Wang L, Zhao Y, Xiong W, Ye W, Zhao W, Hua Y (2019) MicroRNA-449a is downregulated in cervical cancer and inhibits proliferation, migration, and invasion. Oncol Res Treat 42(11):564–571

    Article  CAS  PubMed  Google Scholar 

  23. Zhong J, Yuan H, Xu X, Kong S (2018) MicroRNA-195 inhibits cell proliferation, migration and invasion by targeting defective in cullin neddylation 1 domain containing 1 in cervical cancer. Int J Mol Med 42(2):779–788

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Zhang Z, Wang J, Wang X, Song W, Shi Y, Zhang L (2018) MicroRNA-21 promotes proliferation, migration, and invasion of cervical cancer through targeting TIMP3. Arch Gynecol Obstet 297(2):433–442

    Article  CAS  PubMed  Google Scholar 

  25. Zhang S, Cai J, Xie W, Luo H, Yang F (2018) miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA. Exp Ther Med 16(2):1499–1504

    PubMed  PubMed Central  Google Scholar 

  26. Wang J, Chen J, Sun F, Wang Z, Xu W, Yu Y, Ding F, Shen H (2020) miR-202 functions as a tumor suppressor in hepatocellular carcinoma by targeting HK2. Oncol Lett 19(3):2265–2271

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Gao S, Cao C, Dai Q, Chen J, Tu J (2018) miR-202 acts as a potential tumor suppressor in breast cancer. Oncol Lett 16(1):1155–1162

    PubMed  PubMed Central  Google Scholar 

  28. Dou D, Shi YF, Liu Q, Luo J, Liu JX, Liu M, Liu YY, Li YL, Qiu XD, Tan HY (2018) Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may target DUSP1. World J Gastroenterol 24(5):573–582

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F (2020) Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 8(2):e191–e203

    Article  PubMed  Google Scholar 

  30. Leite KRM, Pimenta R, Canavez J, Canavez F, de Souza FR, Vara L, Estivallet C, Camara-Lopes LH (2020) HPV genotype prevalence and success of vaccination to prevent cervical cancer. Acta Cytol 64(5):420–424

    Article  CAS  PubMed  Google Scholar 

  31. Ediriweera MK, Tennekoon KH, Samarakoon SR (2019) Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol 59:147–160

    Article  CAS  PubMed  Google Scholar 

  32. Polivka J Jr., Janku F (2014) Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 142(2):164–175

    Article  CAS  PubMed  Google Scholar 

  33. Duarte A, Silveira GG, Soave DF, Costa JPO, Silva AR (2019) The role of the LY294002—a non-selective inhibitor of phosphatidylinositol 3-kinase (PI3K) pathway- in cell survival and proliferation in cell line SCC-25. Asian Pac J Cancer Prev 20(11):3377–3383

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bishop JD, Nien WL, Dauphinee SM, Too CK (2006) Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. J Endocrinol 190(2):307–312

    Article  CAS  PubMed  Google Scholar 

  35. Li X, Dai J, Ni D, He X, Zhang H, Zhang J, Fu Q, Liu Y, Lu S (2020) Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B. Int J Biol Macromol 1(144):643–655

    Article  CAS  Google Scholar 

  36. Zhang B, Song Y, Sun S, Han R, Hua C, van der Veen S, Cheng H (2019) Human Papillomavirus 11 early protein E6 activates autophagy by repressing AKT/mTOR and Erk/mTOR. J Virol 93(12):e00172-e219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Deng W, Han W, Fan T, Wang X, Cheng Z, Wan B, Chen J (2018) Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN. Biomed Pharmacother 107:1505–1513

    Article  CAS  PubMed  Google Scholar 

  38. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M (2009) PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 8(9):1352–1358

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Arafeh R, Samuels Y (2019) PIK3CA in cancer: the past 30 years. Semin Cancer Biol 59:36–49

    Article  CAS  PubMed  Google Scholar 

  40. Chen L, Yang L, Yao L, Kuang XY, Zuo WJ, Li S, Qiao F, Liu YR, Cao ZG, Zhou SL, Zhou XY, Yang WT, Shi JX, Huang W, Hu X, Shao ZM (2018) Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun 9(1):1357

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Ranieri C, Di Tommaso S, Loconte DC, Grossi V, Sanese P, Bagnulo R, Susca FC, Forte G, Peserico A, De Luisi A, Bartuli A, Selicorni A, Melis D, Lerone M, Praticò AD, Abbadessa G, Yu Y, Schwartz B, Ruggieri M, Simone C, Resta N (2018) In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS). Neurogenetics 19(2):77–91

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Lachkar B, Minaguchi T, Akiyama A, Liu S, Zhang S, Xu C, Shikama A, Tasaka N, Sakurai M, Nakao S, Ochi H, Yoshikawa H, Satoh T (2018) Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin. Medicine (Baltimore) 97(31):e11392

    Article  CAS  Google Scholar 

  43. Krishnamurthy S, Yoda H, Hiraoka K, Inoue T, Lin J, Shinozaki Y, Watanabe T, Koshikawa N, Takatori A, Nagase H (2021) Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer. Cancer Sci 112(3):1141–1149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Wu Y, Li X, Yu J, Björkholm M, Xu D (2019) ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells. Cell Death Dis 10(2):76

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Guo F, Zhang H, Jia Z, Cui M, Tian J (2018) Chemoresistance and targeting of growth factors/cytokines signalling pathways: towards the development of effective therapeutic strategy for endometrial cancer. Am J Cancer Res 8(7):1317–1331

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Yang W, Feng B, Meng Y, Wang J, Geng B, Cui Q, Zhang H, Yang Y, Yang J (2019) FAM3C-YY1 axis is essential for TGFβ-promoted proliferation and migration of human breast cancer MDA-MB-231 cells via the activation of HSF1. J Cell Mol Med 23(5):3464–3475

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Wan L, Pantel K, Kang Y (2013) Tumor metastasis: moving new biological insights into the clinic. Nat Med 19(11):1450–1464

    Article  CAS  PubMed  Google Scholar 

  48. Smeda M, Kieronska A, Adamski MG, Proniewski B, Sternak M, Mohaissen T, Przyborowski K, Derszniak K, Kaczor D, Stojak M, Buczek E, Jasztal A, Wietrzyk J, Chlopicki S (2018) Nitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice. Breast Cancer Res 20(1):86

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. Gurzu S, Kobori L, Fodor D, Jung I (2019) Epithelial–mesenchymal and endothelial mesenchymal transitions in hepatocellular carcinoma: a review. Biomed Res Int 29(2019):2962580

    Google Scholar 

  50. Caccuri F, Ronca R, Laimbacher AS, Berenzi A, Steimberg N, Campilongo F, Mazzuca P, Giacomini A, Mazzoleni G, Benetti A, Caselli E, Presta M, Di Luca D, Fraefel C, Caruso A (2017) U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis. Oncotarget 8(27):44533–44549

    Article  PubMed  PubMed Central  Google Scholar 

  51. Zhang L, Xu J, Yang G, Li H, Guo X (2018) miR-202 inhibits cell proliferation, migration, and invasion by targeting epidermal growth factor receptor in human bladder cancer. Oncol Res 26(6):949–957

    Article  PubMed  PubMed Central  Google Scholar 

  52. Ding Q, Jin M, Wang Y, Liu J, Kalds P, Wang Y, Yang Y, Wang X, Chen Y (2020) Transactivation of miR-202-5p by Steroidogenic Factor 1 (SF1) induces apoptosis in goat granulosa cells by targeting TGFβR2. Cells 9(2):445

    Article  CAS  PubMed Central  Google Scholar 

  53. Li C, Ma D, Yang J, Lin X, Chen B (2018) miR-202-5p inhibits the migration and invasion of osteosarcoma cells by targeting ROCK1. Oncol Lett 16(1):829–834

    PubMed  PubMed Central  Google Scholar 

  54. Yu HY, Pan SS (2020) MiR-202-5p suppressed cell proliferation, migration and invasion in ovarian cancer via regulating HOXB2. Eur Rev Med Pharmacol Sci 24(5):2256–2263

    PubMed  Google Scholar 

  55. Liu T, Guo J, Zhang X (2019) MiR-202-5p/PTEN mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway. Cancer Biol Ther 20(7):989–998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Dai B, Yu R, Fan M, Yang T, Wang B, Zhang Y (2019) HMQ-T-F2 suppresses migration of the human cervical cancer HeLa cells by reversing EMT via the PI3K/Akt signaling pathway. Oncol Rep 42(4):1451–1458

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

No.

Funding

No.

Author information

Author notes

  1. Yan Zheng and Lei Xie have contributed equally to this work.

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, The First Hospital of Hebei Medical University, No. 89 Donggang Road, Yuhua District, Shijiazhuang City, 050031, Hebei Province, People’s Republic of China

    Yan Zheng, Lei Xie, Shuwen Xu, Hongzhen Zhang, Yali Meng, Jingqiao Liu & Xujing Wei

  2. Training & Research Support Center, Shijiazhuang Camps of the Army Engineering University, Shijiazhuang City, 050031, Hebei Province, People’s Republic of China

    Weidong Yan

Authors
  1. Yan Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lei Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuwen Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Weidong Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hongzhen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yali Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jingqiao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xujing Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YZ, LX, SX, WY, HZ, YM, JL, and XW designed the study, performed the study, analyzed the results and wrote the manuscript. All authors revised the manuscript and agreed to be accountable for all aspects of the presented work.

Corresponding authors

Correspondence to Jingqiao Liu or Xujing Wei.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Consent for publication

All authors have read and agreed to the published version of the manuscript.

Ethical approval

The study was approved by the clinical experimental ethics committee of the First Hospital of Hebei Medical University. All patients had informed consent to the experiment and signed the informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, Y., Xie, L., Xu, S. et al. Effects of miR-202-5p silencing PIK3CA gene expression on proliferation, invasion, and epithelial–mesenchymal transition of cervical cancer SiHa cells through inhibiting PI3K/Akt/mTOR signaling pathway activation. Mol Cell Biochem 476, 4031–4044 (2021). https://doi.org/10.1007/s11010-021-04211-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-021-04211-4

Keywords

Search

Navigation